top of page

IB COMMUNICATIONS PRESS RELEASES

2025

Likarda

12 March 2025

Likarda Receives Grant to Deliver Antibody-Secreting Cell Therapy with CSS® Hydrogel Encapsulation

Kansas City, MO, March 12, 2025 – Likarda, a leading biotech company specializing in the development of enabling technologies for the delivery of both cell therapies and large molecule biologics, announced a new grant from the Gates Foundation that supports the company’s proprietary Core-Shell Spherification® (CSS®) system to extend th....

CellProthera

11 March 2025

CellProthera Presenting at Advanced Therapies Congress 2025 in London  
Ibon Garitaonandia, CellProthera's CSO, will present on “Development of cell-based therapies for Post-acute Myocardial Infarction.” 

Mulhouse, France, March 11, 2025 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases, announced it will be presenting next week at Terrapinn’s Advanced Therapies Congress 2025, held in London. Ibon Garitaonandia, PhD, MBA, Chief Scientific Officer, will present on “Development of cell-based therapies for Post-acute .....

Minoryx

5 March 2025

Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett syndrome (TREE study)

Barcelona, Spain – 5 March 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces that the first patient in the TREE study has been dosed with leriglitazone. TREE is a phase 2a clinical study assessing the safety and efficacy of lead candidate leriglitazone, a novel, brain-penetrant and selective PPAR gamma agonist, to treat patients with Rett syndrome.

Pragmatrix

26 February 2025

Pragmatrix Technology Partners with Achieve Clinics to Transform Cell Therapy Workflows with the PragLife Platform

Chicago, IL, February 26, 2025 – Pragmatrix Technology (“Pragmatrix”), a pioneer in SaaS solutions for the cell therapy industry, proudly announces its partnership with Achieve Clinics (“Achieve”), a Los Angeles, California biotechnology company dedicated to improving patient access to autologous cell therapies. A customized version of PragLife, Pragmatrix’s flagship platform, will now be implemented to support Achieve Clinics' operations end-to-end.

Terumo BCT

25 February 2025

National Alliance of Sickle Cell Centers and Terumo Blood and Cell Technologies Working Together to Improve Outcomes for Patients with Sickle Cell Disease

Lakewood, Colorado, February 25, 2025 – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, announced a partnership with the nonprofit National Alliance of Sickle Cell Centers (NASCC) that aims to improve the lives of people with sickle cell disease (SCD) by addressing gaps in access to blood transfusion therapy and helping....

Green Elephant Biotech

13 February 2025

Working together for a sustainable future: Bürkert Fluid Control Systems and Green Elephant Biotech

Bürkert Fluid Control Systems has taken a stake in Green Elephant Biotech as a strategic investor so the two companies can work together to develop more efficient, flexible and sustainable cell cultivation processes in the pharmaceutical and....

Terumo BCT

29 January 2025

Carter BloodCare First to Complete the Transition to Automated Whole Blood Processing With Terumo Blood and Cell Technologies

Lakewood, Colorado, January 29, 2025 – Terumo Blood and Cell Technologies, a global leader in blood management solutions, today announces that Carter BloodCare is the first U.S. adopter of its Reveos™ Automated Blood Processing System and Lumia™ Software Platform. Carter BloodCare, one of the largest Texas blood centers, is the first to begin....

Reithera

24 January 2025

Reithera and Sillajen Partnership Announced

Rome, Italy January 24th 2025 – ReiThera is proud to announce a new partnership with SillaJen through a comprehensive Master Service Agreement (MSA), which establishes ReiThera as the manufacturing partner for SillaJen’s innovative anticancer virus platform, the SJ-600 series.....

Phacilitate

22 January 2025

Phacilitate Awards Katherine High with the 2025 Lifetime Achievement Award at the Advanced Therapies Awards Ceremony in Dallas

London, UK, January 22, 2025 – Phacilitate, a leading brand that connects advanced therapies industry leaders through inspiring conferences, vibrant communities and market intelligence, today presented Katherine A. High, M.D. with its prestigious Lifetime Achievement Award for 2025. Dr. High, who is now President of Therapeutics at AskBio, has had....

Terumo BCT

21 January 2025

Terumo Blood and Cell Technologies Highlights the Future of Blood in DAVOS Interviews 2025 Film Series

Lakewood, Colorado, January 21, 2025 – Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, believes the future of medicine begins with a single drop of blood. From lifesaving blood transfusions to novel personalized therapies, blood and cells are the foundation of healthcare innovation......

Catalent

21 January 2025

Catalent Announces Collaboration with Galapagos to Further Expand Galapagos’ Decentralized CAR-T Manufacturing Network in the U.S.

January 21 2025 – SOMERSET, NJ – Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic  collaboration with Galapagos NV (Euronext & NASDAQ: GLPG), a biotechnology company with operations in the U.S. and Europe, to support decentralized manufacturing for clinical studies....

Terumo BCT

14 January 2025

Terumo Blood and Cell Technologies and FUJIFILM Irvine Scientific Collaborate to Accelerate T Cell Expansion for Cell Therapy Developers  

Lakewood, COLO. AND SANTA ANA, CALIF., January 14, 2025 – Terumo Blood and Cell Technologies (Terumo BCT), and FUJIFILM Irvine Scientific have announced a strategic collaboration to help accelerate T cell expansion using Fujifilm's PRIME-XV® T Cell Expansion Media on Terumo BCT’s Quantum Flex™ Cell Expansion System. By using systems that work together, this collaboration offers an optimized workflow solution with a ready-to-use process, aimed at reducing the barriers in scaling T cell expansion. 

bottom of page